The abstract is read at the publisher; the summary is JClub's.
In the PECATI phase 2 trial for platinum-refractory advanced B3-thymoma and thymic carcinoma, median progression-free survival reached 22.1 months with 88.0% 5-month PFS.
- Why it matters: Second-line options are lacking for patients with platinum-refractory advanced B3-thymoma and thymic carcinoma, leaving an unmet need for effective post-platinum therapy.
- What they did: In a single-arm study, 43 patients received lenvatinib 20 mg daily plus pembrolizumab 200 mg every 3 weeks in 3-week cycles after at least one platinum regimen.
- The result: Median overall survival was 40.2 months and confirmed ORR was 25.6%, while grade ≥3 treatment-related adverse events occurred in 44.2% with 27.9% discontinuation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.